Menu Close

Actelion boosted by critical drug trials – Financial Times


Bloomberg

Actelion boosted by critical drug trials
Financial Times
By Haig Simonian in Zurich Investors in Actelion breathed a collective sigh of relief on Monday as Europe's biggest biotech group by sales revealed positive test findings for a critical new drug. Basel-based Actelion said a late stage clinical trial
Actelion Says Hypertension Drug Macitentan Met Primary Goals In Pivotal StudyNASDAQ


Actelion to host Conference Call / Audiocast on SERAPHIN Study ResultsReuters
Actelion Lung Drug Meets Main Goal in Pivotal Patient StudyBloomberg
BusinessWeek –MarketWatch
all 29 news articles »

Join the conversation and have a little fun at Capitalstool.com. If you are a new visitor to the Stool, please register and join in! To post your observations and charts, and snide, but good-natured, comments, click here to register. Be sure to respond to the confirmation email which is sent instantly. If not in your inbox, check your spam filter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

RSS
Follow by Email
LinkedIn
Share

Discover more from The Wall Street Examiner

Subscribe now to keep reading and get access to the full archive.

Continue reading